Udenafil    (DrugBank: Udenafil)

2 diseases
IDDisease name (Link within this page)Number of trials
86Pulmonary arterial hypertension2
210Single Ventricle4

86. Pulmonary arterial hypertension    [ 1,083 clinical trials,   667 drugs,   (DrugBank: 122 drugs),   98 drug target genes,   185 drug target pathways]
Searched query = "Pulmonary arterial hypertension", "PAH", "IPAH", "HPAH", "Eisenmenger syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 1,083 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02304198
(ClinicalTrials.gov)
April 201426/11/2014Clinical Trial to Evaluate the Long-term Safety of Udenafil in Patient With PAHA Single-arm, Open-label, Extension Study to Evaluate the Long-term Safety of Udenafil in Patient With Pulmonary Arterial Hypertension(PAH)Pulmonary Arterial HypertensionDrug: UdenafilDong-A ST Co., Ltd.NULLCompleted18 YearsN/ABoth59Phase 2;Phase 3Korea, Republic of
2NCT01553721
(ClinicalTrials.gov)
August 20111/1/2012Efficacy and Safety Study of Udenafil in Patient With Pulmonary Arterial Hypertension(PAH)A Placebo-controlled, Double-blind, Phase II Clinical Study to Evaluate the Efficacy and Safety of Udenafil in Patient With Pulmonary Arterial Hypertension(PAH)Pulmonary Arterial HypertensionDrug: udenafil;Drug: placeboDong-A ST Co., Ltd.NULLCompleted18 YearsN/ABoth63Phase 2Korea, Republic of

210. Single Ventricle    [ 47 clinical trials,   54 drugs,   (DrugBank: 23 drugs),   32 drug target genes,   66 drug target pathways]
Searched query = "Single Ventricle", "SV", "Single ventricle heart defect", "Univentricular heart", "UVH", "Single ventricular circulation syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
4 / 47 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03430583
(ClinicalTrials.gov)
February 20, 201822/1/2018Evaluation of Fontan-Associated Liver DiseaseImaging and Biomarker Evaluation of Hepatic Stiffness in Children Enrolled in the Fontan Udenafil Exercise Longitudinal StudySingle Ventricle Heart DiseaseDrug: MZ101Mezzion Pharma Co. LtdNational Heart, Lung, and Blood Institute (NHLBI)Active, not recruiting12 YearsN/AAll100United States;Canada
2NCT03013751
(ClinicalTrials.gov)
January 20175/1/2017A Extension Study of Udenafil in AdolescentsA Phase III Extension Study of Udenafil in Adolescents With Single Ventricle Physiology After Fontan PalliationFunctional Single Ventricle Heart DiseaseDrug: UdenafilMezzion Pharma Co. LtdNational Heart, Lung, and Blood Institute (NHLBI)Active, not recruiting12 Years18 YearsAll300Phase 3United States;Canada;Korea, Republic of
3NCT02741115
(ClinicalTrials.gov)
July 22, 201610/4/2016Fontan Udenafil Exercise Longitudinal Assessment TrialFontan Udenafil Exercise Longitudinal Assessment Trial (FUEL)Single Ventricle Heart DiseaseDrug: Udenafil;Drug: PlaceboMezzion Pharma Co. LtdNational Heart, Lung, and Blood Institute (NHLBI)Completed12 Years18 YearsAll400Phase 3United States;Canada;Korea, Republic of
4NCT02201342
(ClinicalTrials.gov)
July 201424/7/2014Pharmacokinetic/Pharmacodynamic Study of Udenafil in AdolescentsA Phase I/II Dose Escalation Trial of Udenafil in Adolescents With Single Ventricle Physiology After Fontan PalliationSingle Ventricle Heart Disease After Fontan SurgeryDrug: UdenafilMezzion Pharma Co. LtdNational Heart, Lung, and Blood Institute (NHLBI);Pediatric Heart Network;National Heart, Lung, and Blood Institute (NHLBI);Pediatric Heart NetworkCompleted14 Years18 YearsBoth36Phase 1;Phase 2United States;Canada